These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

835 related items for PubMed ID: 19748990

  • 1. Defucosylated anti-CCR4 monoclonal antibody exerts potent ADCC against primary ATLL cells mediated by autologous human immune cells in NOD/Shi-scid, IL-2R gamma(null) mice in vivo.
    Ito A, Ishida T, Utsunomiya A, Sato F, Mori F, Yano H, Inagaki A, Suzuki S, Takino H, Ri M, Kusumoto S, Komatsu H, Iida S, Inagaki H, Ueda R.
    J Immunol; 2009 Oct 01; 183(7):4782-91. PubMed ID: 19748990
    [Abstract] [Full Text] [Related]

  • 2. Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia/lymphoma.
    Ishii T, Ishida T, Utsunomiya A, Inagaki A, Yano H, Komatsu H, Iida S, Imada K, Uchiyama T, Akinaga S, Shitara K, Ueda R.
    Clin Cancer Res; 2010 Mar 01; 16(5):1520-31. PubMed ID: 20160057
    [Abstract] [Full Text] [Related]

  • 3. Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NOD/Shi-scid, IL-2Rgamma(null) mouse model.
    Ito A, Ishida T, Yano H, Inagaki A, Suzuki S, Sato F, Takino H, Mori F, Ri M, Kusumoto S, Komatsu H, Iida S, Inagaki H, Ueda R.
    Cancer Immunol Immunother; 2009 Aug 01; 58(8):1195-206. PubMed ID: 19048251
    [Abstract] [Full Text] [Related]

  • 4. The CC chemokine receptor 4 as a novel specific molecular target for immunotherapy in adult T-Cell leukemia/lymphoma.
    Ishida T, Iida S, Akatsuka Y, Ishii T, Miyazaki M, Komatsu H, Inagaki H, Okada N, Fujita T, Shitara K, Akinaga S, Takahashi T, Utsunomiya A, Ueda R.
    Clin Cancer Res; 2004 Nov 15; 10(22):7529-39. PubMed ID: 15569983
    [Abstract] [Full Text] [Related]

  • 5. IL-2Ralpha-Directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Ralpha interaction.
    Phillips KE, Herring B, Wilson LA, Rickford MS, Zhang M, Goldman CK, Tso JY, Waldmann TA.
    Cancer Res; 2000 Dec 15; 60(24):6977-84. PubMed ID: 11156399
    [Abstract] [Full Text] [Related]

  • 6. Autologous Tax-specific CTL therapy in a primary adult T cell leukemia/lymphoma cell-bearing NOD/Shi-scid, IL-2Rγnull mouse model.
    Masaki A, Ishida T, Suzuki S, Ito A, Mori F, Sato F, Narita T, Yamada T, Ri M, Kusumoto S, Komatsu H, Tanaka Y, Niimi A, Inagaki H, Iida S, Ueda R.
    J Immunol; 2013 Jul 01; 191(1):135-44. PubMed ID: 23733874
    [Abstract] [Full Text] [Related]

  • 7. Tumor growth suppression by a mouse/human chimeric anti-CEA antibody and lymphokine-activated killer cells in vitro and in SCID mouse xenograft model.
    Senba T, Kuroki M, Arakawa F, Yamamoto T, Kuwahara M, Haruno M, Ikeda S, Matsuoka Y.
    Anticancer Res; 1998 Jul 01; 18(1A):17-24. PubMed ID: 9568050
    [Abstract] [Full Text] [Related]

  • 8. Activating Fc receptors are required for antitumor efficacy of the antibodies directed toward CD25 in a murine model of adult t-cell leukemia.
    Zhang M, Zhang Z, Garmestani K, Goldman CK, Ravetch JV, Brechbiel MW, Carrasquillo JA, Waldmann TA.
    Cancer Res; 2004 Aug 15; 64(16):5825-9. PubMed ID: 15313926
    [Abstract] [Full Text] [Related]

  • 9. In vivo assay of human NK-dependent ADCC using NOD/SCID/gammac(null) (NOG) mice.
    Shiokawa M, Takahashi T, Murakami A, Kita S, Ito M, Sugamura K, Ishii N.
    Biochem Biophys Res Commun; 2010 Sep 03; 399(4):733-7. PubMed ID: 20696130
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The CCR4 as a novel-specific molecular target for immunotherapy in Hodgkin lymphoma.
    Ishida T, Ishii T, Inagaki A, Yano H, Kusumoto S, Ri M, Komatsu H, Iida S, Inagaki H, Ueda R.
    Leukemia; 2006 Dec 03; 20(12):2162-8. PubMed ID: 17039235
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Chimeric and humanized anti-HM1.24 antibodies mediate antibody-dependent cellular cytotoxicity against lung cancer cells.
    Wang W, Nishioka Y, Ozaki S, Jalili A, Verma VK, Hanibuchi M, Abe S, Minakuchi K, Matsumoto T, Sone S.
    Lung Cancer; 2009 Jan 03; 63(1):23-31. PubMed ID: 18524412
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.